Basilea Pharmaceutica AG Fundamental Analysis (SIX: BSLN.SW)
Basilea Pharmaceutica AG (SIX: BSLN.SW) shows strong financial fundamentals with a PE ratio of 15.16, profit margin of 21.15%, and ROE of 36.06%. The company generates $0.2B in annual revenue with strong year-over-year growth of 11.44%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 78.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze BSLN.SW's fundamental strength across five key dimensions:
Efficiency Score
ExcellentBSLN.SW demonstrates superior asset utilization.
Valuation Score
ExcellentBSLN.SW trades at attractive valuation levels.
Growth Score
ModerateBSLN.SW shows steady but slowing expansion.
Financial Health Score
ExcellentBSLN.SW maintains a strong and stable balance sheet.
Profitability Score
ExcellentBSLN.SW achieves industry-leading margins.
Key Financial Metrics
Is BSLN.SW Expensive or Cheap?
P/E Ratio
BSLN.SW trades at 15.16 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, BSLN.SW's PEG of -1.25 indicates potential undervaluation.
Price to Book
The market values Basilea Pharmaceutica AG at 4.92 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 14.02 times EBITDA. This signals the market has high growth expectations.
How Well Does BSLN.SW Make Money?
Net Profit Margin
For every $100 in sales, Basilea Pharmaceutica AG keeps $21.15 as profit after all expenses.
Operating Margin
Core operations generate 23.90 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $36.06 in profit for every $100 of shareholder equity.
ROA
Basilea Pharmaceutica AG generates $17.56 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Basilea Pharmaceutica AG produces operating cash flow of $58.04M, showing steady but balanced cash generation.
Free Cash Flow
Basilea Pharmaceutica AG generates strong free cash flow of $55.33M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $4.47 in free cash annually.
FCF Yield
BSLN.SW converts 6.92% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
15.16
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.25
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.92
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.23
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.51
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.60
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.36
vs 25 benchmark
ROA
Return on assets percentage
0.18
vs 25 benchmark
ROCE
Return on capital employed
0.23
vs 25 benchmark
How BSLN.SW Stacks Against Its Sector Peers
| Metric | BSLN.SW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 15.16 | 30.97 | Better (Cheaper) |
| ROE | 36.06% | 515.00% | Weak |
| Net Margin | 21.15% | 30197.00% | Weak |
| Debt/Equity | 0.51 | 0.53 | Neutral |
| Current Ratio | 6.60 | 5.71 | Strong Liquidity |
| ROA | 17.56% | -16.00% (disorted) | Strong |
BSLN.SW outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Basilea Pharmaceutica AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
53.22%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
329.76%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
196.51%
Industry Style: Defensive, Growth, Innovation
High Growth